Merck discontinues work on COVID-19 vaccines to focus on therapeutics

By The Science Advisory Board staff writers

January 25, 2021 -- Merck will discontinue development of its COVID-19 vaccine candidates because they produced a lower immune response compared to natural infection or other COVID-19 vaccines.

Merck announced the decision following a review of the findings of a phase I clinical study on its COVID-19 vaccine candidates, V590 and V591. While the vaccines were generally well-tolerated, immune responses were lower than what researchers saw following infection or immunization with another vaccine, the company noted.

As a result of the discontinuation, Merck will record a charge in the fourth quarter of 2020 that will affect the company's results under generally accepted accounting principles (GAAP) results but not its non-GAAP results. Merck and collaborators still plan to submit its V590 and V591 phase I study results for publication in scientific journals.

Despite the change, the company plans to continue to advance clinical programs for its investigational medicines, MK-7110 and MK-4482, the later of which, known as molnupiravir, is being developed in conjunction with Ridgeback Bio. Merck also intends to continue evaluating measles virus vector and vesicular stomatitis virus vector-based platforms.

Janux, Merck partner on T-cell engager immunotherapies
Janux Therapeutics has entered into a strategic collaboration and licensing agreement with Merck to discover, develop, and commercialize next-generation...
Merck KGaA, Artios partner on DNA damage response drugs
Artios Pharma and Merck KGaA are set to develop multiple cancer drugs aimed at DNA damage response pathways through a new three-year long research and...
Cue Biopharma, Merck expand Immuno-STAT collaboration
Cue Biopharma has extended the terms of its research collaboration and license agreement with Merck toward developing new clinical candidates for the...
Iktos, Merck collaborate on AI for new drug designs
Artificial intelligence (AI) firm Iktos plans to collaborate with pharmaceutical giant Merck on AI for new drug design.
Merck invests $1B in Seagen
Merck has invested in oncology pharmaceutical developer Seagen in a deal worth $1 billion in equity investment.

Copyright © 2021

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter